Journal
ONCOTARGET
Volume 8, Issue 22, Pages 35508-35522Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16348
Keywords
chronic lymphocytic leukemia; USP7; PTEN; miR181; miR338
Categories
Funding
- Italian Ministero della Salute, Progetto Giovani Ricercatori [GR-2010-2312984, GR-2011-02351167]
- AIRC-Start-Up Grant [2014-15405]
- AIRC [IG 15880 AIRC 2014]
Ask authors/readers for more resources
Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups -those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p) -remain highly challenging. In the present work, we identified USP7, a known de-ubiquitinase with multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) overexpressed through a mechanism involving miR-338-3p and miR-181b deregulation; ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment of primary CLL samples and cell lines with P5091 induces cell growth arrest and apoptosis, through the restoration of PTEN nuclear pool, both in TP53-wild type and -null environment. Importantly, PTEN acts as the main tumor suppressive mediator along the USP7-PTEN axis in a p53 dispensable manner. In conclusion, we propose USP7 as a new druggable target in CLL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available